NIH R01 · 2024
Quinolinate-induced immune suppression in glioblastoma
ABSTRACT Recent advancements using immune checkpoint inhibitors designed to target tumor-mediated immune tolerance have revolutionized cancer therapy. Unfortunately, these clinical successes have not translated to glioblastoma (GBM), which continues to be an invariably fatal malignancy with limited treatment options. One of the leading thoughts in the field explaining this lack of clinical benefit in GBM is that these agents are acting upon the wrong target. Tumor-associated macrophages (TAMs) appear to represent the primary immune cells contributing towards the immune suppressive microenvironment in GBM, vastly outnumbering T cell infiltration. Hence, there is considerable interest in…
From the public funding record at NIH RePORTER. Describes the funded project, not the reviews below.